When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Last reviewed: 20 Apr 2025
Last updated: 29 Apr 2025

Summary

Definition

History and exam

Key diagnostic factors

  • presence of risk factors
  • headache
  • palpitations
  • diaphoresis
  • hypertension
  • hypertensive retinopathy
  • pallor
  • impaired glucose tolerance/diabetes mellitus
  • family history of endocrine disorders
  • history of prior phaeochromocytoma
  • tachyarrhythmias and myocardial infarction
  • panic attacks or a 'sense of doom'

Other diagnostic factors

  • orthostatic hypotension
  • hypercalcaemia
  • Cushing syndrome
  • diarrhoea
  • fever
  • papilloedema
  • abdominal masses
  • tremors

Risk factors

  • multiple endocrine neoplasia type 2 (MEN2)
  • Von Hippel-Lindau (VHL) disease
  • SDHB, SDHC, and SDHD gene mutations
  • neurofibromatosis type 1 (NF1)

Diagnostic investigations

1st investigations to order

  • plasma free metanephrines or 24-hour urine fractionated metanephrines and normetanephrines
  • genetic testing

Investigations to consider

  • FBC
  • serum calcium
  • serum potassium
  • chromogranin A
  • clonidine suppression test
  • CT scan of the abdomen and pelvis
  • MRI of the abdomen and pelvis
  • 18F-fluorodeoxyglucose (18F-FDG) PET/CT or somatostatin receptor-targeted (SSTR) PET/CT with 68Ga-DOTATATE tracer
  • I-123 metaiodobenzylguanidine (MIBG) scintigraphy

Treatment algorithm

Contributors

Authors

Bridget Sinnott, MD
Bridget Sinnott

Professor of Medicine

Medical College of Georgia

Augusta

GA

Disclosures

BS declares that she has no competing interests.

Acknowledgements

Dr Bridget Sinnott would like to gratefully acknowledge Dr Sidhbh Gallagher, a previous contributor to this topic.

Disclosures

SG declares that she has no competing interests.

Peer reviewers

Betul A. Hatipoglu, MD

Clinical Endocrinologist and Research Scientist

Department of Endocrinology, Diabetes, and Metabolism

Cleveland Clinic

Cleveland

OH

Disclosures

BAH declares that she has no competing interests.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and paraganglioma. N Engl J Med. 2019 Aug 8;381(6):552-65. Abstract

Fishbein L, Del Rivero J, Else T, et al. The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and management of metastatic and/or unresectable pheochromocytoma and paraganglioma. Pancreas. 2021 Apr 1;50(4):469-93.Full text  Abstract

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: neuroendocrine and adrenal tumors [internet publication].Full text

Kunz PL, Reidy-Lagunes D, Anthony LB, et al; North American Neuroendocrine Tumor Society. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013 May;42(4):557-77.Full text  Abstract

Plouin PF, Amar L, Dekkers OM, et al; Guideline Working Group. European Society of Endocrinology clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016 May;174(5):G1-10.Full text  Abstract

Reference articles

A full list of sources referenced in this topic is available here.

Use of this content is subject to our disclaimer